Target intelligence / Profile preview

Nanog homeobox pseudogene 2 (NANOGP2)

Target: NANOGP2
Molecular classification: Other (Pseudogene)

Overview

Nanog homeobox pseudogene 2 (NANOGP2) is one of several processed pseudogenes related to the key stem cell transcription factor NANOG. NANOGP2 arises from retrotransposition and does not code for a functional protein. It is located on chromosome 2q36.1 and has no recognized physiological or pathological role. Like most pseudogenes in the NANOG family, it has lost protein-coding potential due to mutations and truncations, and it is not classified as a functional gene or therapeutic target in humans.

Other names: NANOGP2

Biological functions

Other (No established biological function; as a pseudogene, it does not encode a functional protein. Some NANOG pseudogenes may be transcribed at low levels, but there is no evidence for a direct biological or functional role for NANOGP2)

Beyond the preview

Go deeper on Nanog homeobox pseudogene 2 (NANOGP2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanog homeobox pseudogene 2 (NANOGP2).

Explore the full profile